WCM/EADO 2021 | CMP-001 for melanoma and HNSCC

Art Krieg, MD, Checkmate Pharmaceuticals, Cambridge, MA, gives an overview of CMP-001, a virus-like particle which is a CpGA DNA toll-like receptor 9 agonist that can trigger a strong T-cell response. Intratumoral injection of CMP-001 can direct T-cells towards tumors. CMP-001 is currently being trialled in combination with pembrolizumab for patients with melanoma in the CMP-001-002 trial (NCT03084640), and in patients with head and neck squamous cell carcinoma (HNSCC) in the CMP-001-007 trial (NCT04633278). This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.